Chronic Renal Failure Clinical Trial
Official title:
The Effect of Dexmedetomine Premedication on the Bispectral Index Values Using Sedation With Propofol During Spinal Anesthesia on Geriatric Chronic Renal Failure Patients Undergoing Hip Fracture Surgery The Effect of Dexmedetomine Premedication on the Bispectral Index Values Using Sedation With Propofol During Spinal Anesthesia on Geriatric Chronic Renal Failure Patients Undergoing Hip Fracture Surgery
Verified date | January 2015 |
Source | Baskent University |
Contact | n/a |
Is FDA regulated | No |
Health authority | Turkey: Ethics Committee |
Study type | Interventional |
Geriatric patients (age ≥ 65 years) undergo surgery for hip fractures that develops due to
osteoporosis and falls. Dialysis-dependent chronic kidney disease is associated with an
increased risk of cardiovascular comorbidity. Elective or urgent surgical operations may be
required for geriatric patients with end stage renal disease. These patients have severe
comorbidities, fluid, electrolyte disturbances and drug metabolism abnormalities during the
perioperative period. For this reasons a careful anesthesia plan should be planned and
performed. Spinal anesthesia can be used for hip fracture surgery at geriatric patients with
chronic renal failure. Anterograde femoral intramedullary nailing can be performed in supine
position with a fracture table. Intraoperative sedation might be necessary for patients
under regional anesthesia on traction table. Dexmedetomidine is an alpha 2 receptor agonist
that is being used as an agent for its sedative and adjuvant analgesic effects.
The aim of this study is to evaluate the effects of dexmedetomidine premedication on
geriatric patients with end stage renal disease, who will be undergoing a surgical operation
for hip fracture under spinal anesthesia with hyperbaric bupivacaine and BIS (Bispectral
Index) guided sedation with intraoperative propofol infusion.
Status | Completed |
Enrollment | 60 |
Est. completion date | January 2014 |
Est. primary completion date | January 2014 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 65 Years to 95 Years |
Eligibility |
Inclusion Criteria: - elderly patients (above 65 years of age) - end stage renal failure on dialysis treatment (Glomerular filtration rate <15, Stage 5) - hip fracture Exclusion Criteria: - Patients with decompensated respiratory or heart failure, - liver failure - morbid obesity - mental disorders - cognitive disorders - language problems - patients with a contraindication for regional anesthesia (coagulopathy, history of anticoagulant use, spinal cord disease and patients who rejected spinal anesthesia) |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)
Country | Name | City | State |
---|---|---|---|
Turkey | Baskent University School of Medicine Adana Research and Teaching Center | Adana | |
Turkey | Baskent University School of Medicine Adana Teaching and Research Center | Adana | |
Turkey | Baskent University School of Medicine Adana Teaching and Research Hospital | Adana |
Lead Sponsor | Collaborator |
---|---|
Baskent University |
Turkey,
Ozkan-Seyhan T, Sungur MO, Senturk E, Karadeniz M, Basel A, Senturk M, Akpir K. BIS guided sedation with propofol during spinal anaesthesia: influence of anaesthetic level on sedation requirement. Br J Anaesth. 2006 May;96(5):645-9. Epub 2006 Mar 10. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Decrease at the propofol doses and postoperative early recovery | In addition patients will be followed postoperatively first 6 hours for postoperative pain management at the ward. | up to first 6 hours for postoperative pain management | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT02565459 -
MSC and Kidney Transplant Tolerance (Phase A)
|
Phase 1 | |
Recruiting |
NCT02356419 -
rESP Medication With a Single Intravenous Administration and Dose Escalation to Explore the Tolerability ,Safety and Pharmacokinetic Characteristics
|
Phase 1 | |
Recruiting |
NCT01876017 -
Safety and Efficacy of BMMNC in Patients With Chronic Renal Failure
|
Phase 1/Phase 2 | |
Withdrawn |
NCT03019159 -
Assessment of a Follow-up With Tele-consulting for Patients With Renal Failure Under Peritoneal Dialysis
|
N/A | |
Completed |
NCT02047006 -
Dose-finding of Rivaroxaban in Hemodialysis
|
Phase 4 | |
Completed |
NCT01617824 -
Rapid Effects Linagliptin on Monocyte Polarization and Endothelial Progenitor Cells in Type 2 Diabetes
|
Phase 4 | |
Completed |
NCT00597753 -
Safety & Efficacy of Peginesatide for Maintenance Treatment of Anemia in Participants With Chronic Kidney Disease on Hemodialysis
|
Phase 3 | |
Completed |
NCT00828776 -
Pharmacodynamics and Non-Clinical Inferiority of Heparin Sodium (Cristália) Compared With the Product Liquemine (Roche) in Chronic Renal Failure
|
Phase 2/Phase 3 | |
Completed |
NCT00379899 -
ADVANCE: Study to Evaluate Cinacalcet Plus Low Dose Vitamin D on Vascular Calcification in Subjects With Chronic Kidney Disease Receiving Hemodialysis
|
Phase 4 | |
Terminated |
NCT00372489 -
Extension Study to Evaluate Safety and Tolerability of Peginesatide for Long-Term Treatment of Anemia in Participants With CKD
|
Phase 2 | |
Completed |
NCT00228436 -
Safety, PD & PK of Multiple Doses of Peginesatide for Anemia in Chronic Kidney Disease Patients
|
Phase 2 | |
Completed |
NCT03772171 -
Estimate for Dietary Intakes and Hemodialysis Patients
|
||
Recruiting |
NCT02586402 -
Safety & Efficacy of Pegolsihematide for Treatment of Anemia in Participants on Dialysis
|
Phase 2 | |
Completed |
NCT01879618 -
Use Of Fragmin In Hemodialysis
|
Phase 3 | |
Not yet recruiting |
NCT01346215 -
Study of Clinical Non-inferiority of Actparin® (Laboratorio Bergamo) Compared to Heparin Sodium (APP Pharmaceuticals), in Patients With Chronic Renal Failure
|
Phase 3 | |
Completed |
NCT01220843 -
FGF23 Reduction : Efficacy of a New Phosphate Binder in CHronic Kidney Disease
|
Phase 3 | |
Completed |
NCT01111630 -
Study of Erythropoietin (EPO) Administration Schedule
|
Phase 4 | |
Completed |
NCT00742716 -
Safety Study of CTA018 Injection to Treat Stage 5 Chronic Kidney Disease
|
Phase 2 | |
Completed |
NCT00598273 -
Safety & Efficacy of Peginesatide for the Treatment of Anemia in Participants With Chronic Renal Failure Not on Dialysis
|
Phase 3 | |
Completed |
NCT00597584 -
Safety & Efficacy of Peginesatide for Maintenance Treatment of Anemia in Participants With Chronic Kidney Disease on Hemodialysis
|
Phase 3 |